businesspress24.com - NuPathe to Report Fourth Quarter and Full Year 2011 Results and Hold Conference Call on Tuesday, Mar
 

NuPathe to Report Fourth Quarter and Full Year 2011 Results and Hold Conference Call on Tuesday, March 20, 2012

ID: 1092179

(firmenpresse) - CONSHOHOCKEN, PA -- (Marketwire) -- 03/13/12 -- NuPathe Inc. (NASDAQ: PATH), a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, will report fourth quarter and full year 2011 results on Tuesday, March 20, 2012, before the open of the U.S. financial markets. NuPathe will also host a conference call at 8:30 a.m. EDT on the same day to discuss its fourth quarter and full year 2011 financial results and recent operational highlights. A question-and-answer session will follow NuPathe's remarks.

To participate on the live call, please dial 888-797-2982 (domestic) or +1-913-312-0380 (international), and provide the participant passcode 8797224 five to ten minutes before the start of the call. A replay of the call will be available for 90 days within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 8797224.

A live audio webcast of the call will be also available via the "Investor Relations" page of the NuPathe website, . Please log on through NuPathe's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on NuPathe's website for 90 days following the call.

Inc. is a biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, , is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two proprietary product candidates in preclinical development: for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. NuPathe is actively seeking partnerships to maximize the commercial potential for our pipeline products in the U.S. and territories throughout the world.





For more information about NuPathe, please visit our website and our blog at . You can also follow us on StockTwits (), Twitter (), SlideShare (), and LinkedIn ().



John Woolford
Westwicke Partners, LLC
(443) 213-0506


Keith A. Goldan
Vice President & Chief Financial Officer
NuPathe Inc.
(484) 567-0130


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Cornerstone Therapeutics Receives FDA Acceptance for CRTX 080 NDA for Treatment of Hyponatremia
WorldCare Clinical Introduces New 24-Hour Turnaround Services for Imaging Safety Reviews
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 13.03.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 1092179
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

CONSHOHOCKEN, PA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 99 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"NuPathe to Report Fourth Quarter and Full Year 2011 Results and Hold Conference Call on Tuesday, March 20, 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von

NuPathe Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von NuPathe Inc.



 

Who is online

All members: 10 568
Register today: 1
Register yesterday: 2
Members online: 0
Guests online: 87


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.